Release Date: 28/05/18 09:02 Summary: Further Goulamina Cost Reductions Price Sensitive: Yes Download Document 619.58KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%